Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol
Conditions
Interventions
Bumetanide
Placebo
Locations
1
United Kingdom
MRC Centre for Neuromuscular Disorders
London, United Kingdom
Start Date
January 1, 2015
Primary Completion Date
May 9, 2017
Completion Date
May 9, 2017
Last Updated
February 7, 2018
Lead Sponsor
University College, London
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions